Cargando…
Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States
(1) Background: Drug lag, the delay between the first global regulatory approval and approval by the national health authorities in other countries, impacts the accessibility of drugs. Although the Korean pharmaceutical market has grown significantly, most of its innovative drugs for public health d...
Autores principales: | Cho, Inhye, Han, Euna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910054/ https://www.ncbi.nlm.nih.gov/pubmed/35270550 http://dx.doi.org/10.3390/ijerph19052857 |
Ejemplares similares
-
International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States
por: Song, Yun‐Kyoung, et al.
Publicado: (2019) -
Comparing cancer drug approval systems in the United States and Japan
por: Kaneda, Yudai, et al.
Publicado: (2023) -
Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States
por: Lee, Mijin, et al.
Publicado: (2023) -
An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004–2018)
por: Konwar, Mahanjit, et al.
Publicado: (2021) -
A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States
por: Hoshino, Yuko, et al.
Publicado: (2022)